ReviewEuropean journal of pharmacology2015
New targets to treat obesity and the metabolic syndrome.
Review in European journal of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Effects of Grape Seed Proanthocyanidin Extract on Obesity.Obesity facts · 2020Pooled it
- Robotic Versus Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity: a Systematic Review and Meta-Analysis.Obesity surgery · 2018Pooled it
- Trial
- A dose-response relationship between low-density lipoprotein cholesterol levels within the normal range and the incidence of diabetes mellitus: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Exploring the interplay between circadian rhythms and obesity: A Boolean network approach to understanding metabolic dysregulation.PloS one · 2025Article
- High-fat diet stimulated butyric acid metabolism dysbiosis, altered microbiota, and aggravated inflammatory response in collagen-induced arthritis rats.Nutrition & metabolism · 2024Article
- High fat diet increases the severity of collagen-induced arthritis in mice by altering the gut microbial community.Advances in rheumatology (London, England) · 2024Article
- Association between body mass index and mental health among nurses: a cross-sectional study in China.BMC health services research · 2024Article
- Supplementation with okra combined or not with exercise training is able to protect the heart of animals with metabolic syndrome.Scientific reports · 2023Article
- Plant bioactive compounds from Mediterranean diet improve risk factors for metabolic syndrome.International journal of food sciences and nutrition · 2023Review
- Pharmacokinetics ofInternational journal of molecular sciences · 2022Article
- Determinants of metabolic syndrome among patients attending diabetes clinics in two sub-urban hospitals: Bono Region, Ghana.BMC cardiovascular disorders · 2022Article
- Regulation of appetite-related neuropeptides by Panax ginseng: A novel approach for obesity treatment.Journal of ginseng research · 2022Review
- Discovery and Characterization of the Naturally Occurring Inhibitors Against Human Pancreatic Lipase inFrontiers in nutrition · 2022Article
- Burden of Metabolic Syndrome Among a Low-Income Population in China: A Population-Based Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Effects of In Vitro Muscle Contraction on Thermogenic Protein Levels in Co-Cultured Adipocytes.Life (Basel, Switzerland) · 2021Article
- Study of the Potential Hepatoprotective Effect of Myo-Inositol and Its Influence on Zebrafish Development.Nutrients · 2021Article
- Intrauterine growth restriction weakens anticontractile influence of NO in coronary arteries of adult rats.Scientific reports · 2021Article
- Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis.Medical oncology (Northwood, London, England) · 2021Article
- The Neural Network of Neuropeptide S (NPS): Implications in Food Intake and Gastrointestinal Functions.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Metabolic syndrome (MetS) is a cluster ofassociated metabolic traits that collectively confer unsurpassed risk for development of cardiovascular disease (CVD) and type 2 diabetes compared to any single CVD risk factor. Truncal obesity plays an exceptionally critical role among all metabolic traits of the MetS. Consequently, the prevalence of the MetS has steadily increased with the growing epidemic of obesity. Pharmacotherapy has been available for obesity for more than one decade, but with little success in improving the metabolic profiles. The serotonergic drugs and inhibitors of pancreatic lipases were among the few drugs that were initially approved to treat obesity. At the present time, only the pancreatic lipase inhibitor orlistat is approved for long-term treatment of obesity. New classes of anti-diabetic drugs, including glucagon-like peptide 1 receptor (GLP-1R) agonists and Dipeptidyl-peptidase IV (DPP-IV) inhibitors, are currently being evaluated for their effects on obesity and metabolic traits. The genetic studies of obesity and metabolic syndrome have identified novel molecules acting on the hunger and satiety peptidergic signaling of the gut-hypothalamus axis or the melanocortin system of the brain and are promising targets for future drug development. The goal is to develop drugs that not only treat obesity, but also favorably impact its associated traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.